Coherus Acquires Bevacizumab Rights From Innovent
Deal Also Includes Option To Sell Innovent’s Rituximab Biosimilar
Coherus BioSciences has struck a deal with China’s Innovent Biologics that gives it US and Canadian rights to a bevacizumab biosimilar version of Avastin as well as an option to market Innovent’s rituximab rival to Rituxan in the US and Canada.
You may also be interested in...
Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
Buoyed by the success of its Udenyca pegfilgrastim biosimilar, Coherus has struck a deal with Bioeq to acquire commercialization rights to its biosimilar version of Lucentis (ranibizumab) in the US, eyeing a launch date of 2021.